| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| SCYNEXIS INC | Chief Commercial Officer | Common Stock | 58,200 | $174,600 | $3.00 | 04 Feb 2022 | Direct |
| Iterum Therapeutics plc | Chief Commercial Officer | Share Option (Right to Buy) | 200,000 | 01 Jul 2025 | Direct | ||
| SCYNEXIS INC | Chief Commercial Officer | Stock Option (Right to Buy) | 75,000 | 04 Feb 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ITRM | Iterum Therapeutics plc | 01 Jul 2025 | 1 | $0 | 4 | Chief Commercial Officer | 03 Jul 2025, 16:16 |
| ITRM | Iterum Therapeutics plc | 01 Jul 2025 | 0 | $0 | 3 | Chief Commercial Officer | 03 Jul 2025, 16:15 |
| SCYX | SCYNEXIS INC | 04 Feb 2022 | 2 | $0 | 4 | Chief Commercial Officer | 08 Feb 2022, 15:12 |
| SCYX | SCYNEXIS INC | 10 May 2021 | 2 | $0 | 4 | Chief Commercial Officer | 12 May 2021, 20:26 |
| SCYX | SCYNEXIS INC | 10 May 2021 | 0 | $0 | 3 | Chief Commercial Officer | 12 May 2021, 20:24 |